Symmetrel: Effective Antiviral and Parkinson's Symptom Management
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.35 | $40.42 (0%) | 🛒 Add to cart |
| 60 | $1.06 | $80.84 $63.64 (21%) | 🛒 Add to cart |
| 90 | $0.97 | $121.26 $87.72 (28%) | 🛒 Add to cart |
| 120 | $0.90 | $161.68 $107.50 (34%) | 🛒 Add to cart |
| 180 | $0.82 | $242.52 $147.06 (39%) | 🛒 Add to cart |
| 270 | $0.77 | $363.78 $208.98 (43%) | 🛒 Add to cart |
| 360 | $0.73
Best per pill | $485.04 $263.16 (46%) | 🛒 Add to cart |
Synonyms | |||
Symmetrel (amantadine hydrochloride) is a well-established antiviral and antiparkinsonian agent with a unique dual mechanism of action. This medication has demonstrated clinical efficacy for both influenza A virus prophylaxis and the management of Parkinson’s disease symptoms, including drug-induced extrapyramidal reactions. Its pharmacological profile includes antiviral activity against influenza A strains and dopaminergic effects that help restore neurotransmitter balance in basal ganglia circuits. With decades of clinical use and extensive research supporting its safety profile, Symmetrel remains a valuable therapeutic option in appropriate patient populations when administered under proper medical supervision.
Features
- Contains amantadine hydrochloride as the active pharmaceutical ingredient
- Available in 100 mg capsule and syrup formulations (50 mg/5 mL)
- Exhibits both antiviral and dopaminergic pharmacological activity
- Demonstrated efficacy against influenza A virus strains
- Shows activity in managing parkinsonian symptoms and drug-induced extrapyramidal reactions
- Established safety profile with extensive clinical use history
Benefits
- Provides effective prophylaxis against influenza A virus infection in high-risk populations
- Reduces severity and duration of influenza A symptoms when administered early in infection
- Improves motor symptoms in Parkinson’s disease, including bradykinesia, rigidity, and tremor
- Helps manage drug-induced extrapyramidal symptoms caused by neuroleptic medications
- Offers convenient once or twice daily dosing regimens for improved compliance
- Serves as adjunctive therapy that may allow reduction of other antiparkinsonian medications
Common use
Symmetrel is primarily indicated for the prophylaxis and treatment of respiratory tract illnesses caused by influenza A virus strains. In neurology, it is used for the treatment of Parkinson’s disease, particularly for managing the symptoms of parkinsonism and drug-induced extrapyramidal reactions. The medication may be employed as monotherapy in early Parkinson’s disease or as adjunctive therapy with levodopa in more advanced cases. For influenza prophylaxis, it is particularly valuable in institutional settings and for high-risk patients who cannot receive influenza vaccine or require additional protection.
Dosage and direction
For influenza A treatment in adults: 200 mg daily as a single dose or 100 mg twice daily. For prophylaxis: 200 mg daily or 100 mg twice daily. For Parkinson’s disease: Initial dose of 100 mg daily, increasing to 100 mg twice daily after one week if necessary. For patients with serious associated medical illnesses or those receiving high doses of other antiparkinson drugs: 100 mg daily. Elderly patients may require reduced dosage. The syrup formulation should be administered using proper measuring devices. Treatment duration varies by indication, with influenza prophylaxis typically continuing throughout the risk period.
Precautions
Patients with history of seizures should be monitored closely, as Symmetrel may lower seizure threshold. Those with congestive heart failure, peripheral edema, or orthostatic hypotension require careful supervision. Renal function should be assessed before and during treatment, with dosage adjustments for impaired renal function. Mental status changes, including depression and suicidal ideation, have been reported and require monitoring. Patients should avoid abrupt discontinuation, which may precipitate parkinsonian crisis. Caution is advised when operating machinery or driving until response is determined.
Contraindications
Hypersensitivity to amantadine or any component of the formulation. The drug is contraindicated in patients with end-stage renal disease (creatinine clearance <15 mL/min). Should not be administered concurrently with live attenuated influenza vaccine. Avoid use in patients with untreated angle-closure glaucoma. Not recommended during pregnancy unless potential benefits outweigh risks. Contraindicated in breastfeeding women due to secretion in human milk.
Possible side effect
Common adverse reactions include nausea, dizziness, lightheadedness, and insomnia. Neuropsychiatric effects may include anxiety, irritability, hallucinations, and confusion. Less frequently reported are livedo reticularis, peripheral edema, and orthostatic hypotension. Anticholinergic effects such as dry mouth, blurred vision, and urinary retention may occur. Gastrointestinal disturbances including constipation and anorexia have been reported. Most side effects are dose-dependent and often diminish with continued therapy or dosage reduction.
Drug interaction
Symmetrel exhibits multiple potential drug interactions. Anticholinergic drugs may potentiate anticholinergic side effects. Concurrent use with CNS stimulants may increase nervousness, irritability, insomnia, or seizures. Hydrochlorothiazide and triamterene may decrease amantadine clearance. QT-prolonging agents may have additive effects on cardiac repolarization. Alcohol may increase CNS effects such as dizziness and confusion. Co-administration with memantine should be avoided due to similar mechanisms.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next dose. Patients should not double the dose to make up for a missed dose. For twice-daily regimens, if missed and remembered within 4 hours of scheduled time, take immediately. If beyond 4 hours, skip the missed dose and resume regular schedule. Maintaining consistent dosing is important for therapeutic effect, particularly in Parkinson’s disease management.
Overdose
Symptoms of overdose may include agitation, hallucinations, cardiac arrhythmias, hyperthermia, and respiratory distress. Severe overdose may lead to convulsions, coma, and death. Management includes gastric lavage if presented early, supportive care, and symptomatic treatment. Acidification of urine may enhance elimination. Hemodialysis may be effective in removing the drug. Cardiac monitoring is essential, as fatal cardiac arrhythmias have been reported with massive overdose.
Storage
Store at controlled room temperature (20-25°C or 68-77°F). Protect from light and moisture. Keep container tightly closed. Do not freeze the syrup formulation. Keep out of reach of children and pets. Discard any unused medication after the expiration date. Do not transfer capsules to other containers unless specifically designed for medication storage.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Symmetrel should only be used under the supervision of a qualified healthcare professional. Individual response to medication may vary. Patients should consult their physician for diagnosis and appropriate treatment recommendations. The complete prescribing information should be reviewed before initiating therapy.
Reviews
Clinical studies have demonstrated Symmetrel’s efficacy in reducing influenza A infection rates by 50-70% when used for prophylaxis. In Parkinson’s disease, approximately 60-70% of patients show meaningful improvement in motor symptoms. Many clinicians note its particular value in managing levodopa-induced dyskinesias. The drug is generally well-tolerated, though side effects may limit use in some elderly patients. Long-term experience supports its position as a valuable therapeutic option when appropriately prescribed.